Form 4: Adicet Bio Director Steve Dubin Reports Significant Equity Grant

Adicet Bio, Inc. Director Steve Dubin has reported the acquisition of 5,900 Restricted Stock Units and 26,400 stock options as part of his compensation, increasing his beneficial ownership in the company.

Summary

• Steve Dubin, a Director of Adicet Bio, Inc. (ACET), reported new equity grants on June 11, 2025.
• He acquired 5,900 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a grant price of $0.
• He also acquired 26,400 stock options with an exercise price of $0.78 per share, which expire on June 10, 2035.
• Both the RSUs and stock options are subject to vesting conditions: they will vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders, contingent on his continued service on the Issuer's board of directors.
• Following these transactions, Mr. Dubin beneficially owns 22,700 shares of Common Stock and 26,400 stock options.

Sentiment

Score: 7

Explanation: The filing reports a routine equity grant to a director, which is a positive for aligning interests but does not represent a new investment or significant strategic shift.

Positives

• The issuance of equity grants to a director aligns their financial interests with those of the company's shareholders, encouraging long-term commitment and performance.
• The grants are part of a standard compensation package, indicating continued engagement and commitment of the director to the company's governance.

Negatives

• The transaction does not involve a direct cash investment by the director, as it is an equity grant rather than an open market purchase.

Risks

• The vesting of the Restricted Stock Units and stock options is contingent upon the director's continued service on the board of directors, meaning the full value is not realized if service ceases before vesting.

Future Outlook

The equity grants are subject to future vesting, contingent on the director's continued service on the board, indicating a forward-looking commitment from the director to the company's performance.

Management Comments

• "The Reporting Person was issued Restricted Stock Units ('RSUs'). Each RSU represents a contingent right to receive one share of Common Stock."
• "The RSUs shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors."
• "These shares [stock options] shall vest in full on the earlier to occur of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service on the Issuer's board of directors."

Industry Context

This transaction is a routine compensation event for a director of a publicly traded company, common across various industries, including biotechnology, to align executive and board interests with shareholder value.

Related Party Transactions

• Grant of 5,900 Restricted Stock Units (RSUs) and 26,400 stock options to Steve Dubin, a Director of Adicet Bio, Inc., as part of his compensation.

Stakeholder Impact

• Shareholders: The equity grants are intended to align the director's interests with those of shareholders, potentially leading to more shareholder-friendly decisions and long-term value creation.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The RSUs and stock options will vest according to the specified schedule, contingent on the director's continued service.
• The director may choose to exercise the stock options at or after their vesting date, prior to their expiration.

Key Dates

Recommendation

Keywords

Adicet Bio, ACET, SEC Form 4, Insider Transaction, Director Compensation, Equity Grant, Restricted Stock Units, Stock Options, Beneficial Ownership